News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News AbbVie turbocharges its US investment promise to $100bn AbbVie finally agrees a most-favoured nation pricing deal with the US administration, with a $100 billion investment promise attached.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
